Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors

NCT05334329 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT05334329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05334329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
Lead sponsor
University of California, Irvine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 20, 2022
Completion date
November 30, 2028
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung non-small cell carcinoma, metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, refractory lung non-small cell carcinoma, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8